Clinical Trial Update: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) [Phase 2]

View source ↗

Summary

Phase 2 update from the Pediatric MATCH trial describes targeted therapies matched to tumor genetics in pediatric patients with relapsed or refractory advanced …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Langerhans Cell Histiocytosis
• Medulloblastoma
• Neuroblastoma
• Non-hodgkin Lymphoma
• Osteosarcoma
• Soft Tissue Sarcoma
• Wilms Tumor

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-14